Log inSign up
user avatar
Telix Pharmaceuticals
@TelixPharma
Global biopharma company developing radiopharmaceuticals to address unmet medical need in oncology and rare diseases. ASX: TLX | NASDAQ: TLX
Melbourne, Victoria
telixpharma.com
Joined December 2016
617
Following
1,875
Followers
  • user avatar
    Telix Pharmaceuticals
    @TelixPharma
    Dec 19, 2021
    Telix’s lead product for prostate cancer has been approved by the US FDA as a diagnostic agent for staging in newly diagnosed patients, or in patients with suspected recurrence.​ More on our website: bit.ly/3s4baZa Full prescribing information: bit.ly/3e7bPRG
    FDA Approves Telix’s Prostate Cancer Imaging Product
  • user avatar
    Telix Pharmaceuticals
    @TelixPharma
    Nov 6, 2022
    Telix is pleased to today announce that the pivotal Phase III ZIRCON study of its investigational kidney cancer imaging agent TLX250-CDx has met its co-primary and key secondary endpoints, exceeding targets for sensitivity and specificity. More here: telixpharma.com/news-views/zir…
    ZIRCON Phase III top-line data: study meets primary objectives
  • user avatar
    Telix Pharmaceuticals
    @TelixPharma
    Dec 20, 2021
    We are pleased to announce the FDA has approved Telix's lead product as a diagnostic agent for prostate cancer, heralding a new era of patient and physician access to gallium-based PSMA-PET imaging. More on our website: bit.ly/3s4baZa #TelixPharma #PSMAPET #GalliumWave
    FDA Approves Telix’s Prostate Cancer Imaging Product
  • user avatar
    Telix Pharmaceuticals
    @TelixPharma
    Aug 8, 2022
    Telix has been jointly awarded a $5 million Australian Research Council (ARC) grant to establish a research hub for novel radiopharmaceuticals. Thanks to Prof Kristofer Thurecht at @UQ_News for leading a successful application and ARC for funding. More: bit.ly/3QtHhdE
    Telix part of University of Queensland-led consortium awarded $4.8 million Australian Research Council (ARC) grant to establish research hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR)
  • user avatar
    Telix Pharmaceuticals
    @TelixPharma
    Jul 13, 2022
    What a journey! The #EAU22 Telix PSMA symposium with Dr @CaPsurvivorship, Prof @stefanofanti4 & Prof Jochen Walz was an insightful discussion. Thank you to all the travellers who took part – with you onboard, the train is moving fast! Next stop: applying learnings to practice.
    00:00
  • user avatar
    Telix Pharmaceuticals
    @TelixPharma
    Feb 25, 2025
    The U.S. FDA has accepted Telix’sBiologics License Application (BLA) for its investigational kidney cancer imaging agent TLX250-CDx (Zircaix®, 89Zr-DFO-girentuximab), granting a Priority Review with a PDUFA date of August 27, 2025. This acceptance brings this breakthrough
    2.3K
  • user avatar
    Telix Pharmaceuticals
    @TelixPharma
    Feb 9, 2022
    Today Telix officially joins the S&P/ASX 200 Index, effective prior to the open of trading. We would like to acknowledge the commitment of our staff, Board and partners, as well as the patients and investors who have supported Telix’s journey to date. #TelixPharma #ASX200
    Telix today enters into the S&P/ASX 200 Index, effective prior to the open of trading
  • user avatar
    Telix Pharmaceuticals
    @TelixPharma
    Nov 1, 2021
    Telix is delighted to announce the TGA has approved Illuccix® for prostate cancer imaging. We are especially pleased to receive our first regulatory approval in our home market, and look forward to bringing PSMA-PET imaging to patients across Australia. bit.ly/3wa3B3o
    Australian TGA Approves Illuccix® for Prostate Cancer Imaging
  • user avatar
    Telix Pharmaceuticals
    @TelixPharma
    Oct 27, 2022
    Telix is excited to announce it has been named Australian Company of the Year in the 2022 @AusBiotech and @JNJInnovation Industry Excellence Awards. We are honoured to be recognised, and proud to be a part of Australia’s world-class life sciences sector. bit.ly/3TG4BHr
    Telix is excited to announce that it has been named Australian Company of the Year in the 2022 AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards.
  • user avatar
    Telix Pharmaceuticals
    @TelixPharma
    Jan 27, 2025
    Today, we formally welcome RLS Radiopharmacies into the Telix Group of companies, with the completion of the acquisition. This immediately enhances Telix’s presence in the United States (U.S.), with a network of over 30 radiopharmacies By uniting Telix’s industry-leading
    00:00
    1.3K
  • user avatar
    Telix Pharmaceuticals
    @TelixPharma
    Mar 20, 2025
    The FDA has approved Gozellix® (TLX007-CDx), Telix’s next-generation PSMA-PET imaging agent for prostate cancer. Gozellix® is a novel product with a longer shelf life and an extended distribution radius compared to existing gallium-based imaging products. The ability to
    00:00
    2.6K
  • user avatar
    Telix Pharmaceuticals
    @TelixPharma
    Nov 13, 2024
    Today marked an important milestone for Telix as we commenced trading on the @Nasdaq under the ticker “TLX”. We reaffirm our founding commitment to building a world-class global business, that delivers on the promise of precision medicine through targeted radiation, helping
    GIF
    761
  • user avatar
    Telix Pharmaceuticals
    @TelixPharma
    Nov 23, 2020
    In what is a major milestone for the company, Telix is delighted to announce that its first commercial New Drug Application for TLX591-CDx, for #ProstateCancer imaging, has been accepted for filing by the U.S. FDA. ASX release: bit.ly/3m047Ld #TelixPharma #SeeItTreatIt
  • user avatar
    Telix Pharmaceuticals
    @TelixPharma
    Oct 10, 2022
    Telix is in Barcelona for this year’s EANM! Our symposium ‘Shifting perspectives in Genitourinary Oncology through nuclear medicine’ will take place on Sunday 16.10 from 13:15-14:45. See you there for what promises to be a fascinating discussion. bit.ly/3SRtorB #EANM22
    00:00